<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140462</url>
  </required_header>
  <id_info>
    <org_study_id>201612023RIND</org_study_id>
    <nct_id>NCT03140462</nct_id>
  </id_info>
  <brief_title>Influence of Genetic Polymorphism of Donor on Tacrolimus Concentration in Liver Transplant</brief_title>
  <official_title>The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism of Donor on Tacrolimus Blood Concentration in Liver Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the influence of donor's ABCB1、CYP3A4、CYP3A5、POR genetic polymorphism on tacrolimus&#xD;
      blood concentration in liver transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will start with a retrospective data analysis. The investigators will use the&#xD;
      electronic databases of National Taiwan University Hospital to identify patients who&#xD;
      underwent liver transplantation, received tacrolimus and were still followed up at the&#xD;
      outpatient clinic. Inclusion and exclusion criteria will be applied to screen appropriate&#xD;
      participants, and find their donors. And analyze the effect of genetic polymorphism&#xD;
      (ABCB1、CYP3A4、CYP3A5、POR) of donors, including other factors of recipients, on the dose&#xD;
      normalized trough concentration of tacrolimus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">April 12, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dose normalized trough concentration of tacrolimus in liver transplant patients within the first 6 months post-transplantation</measure>
    <time_frame>Within the first 6 months post-transplantation</time_frame>
    <description>Analyse the effect of the donor's genetic polymorphism to dose normalized trough concentration of tacrolimus in liver transplant patients. Trough level of tacrolimus was adjusted by liver recipient's body weight.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">96</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>liver transplant patients and donors</arm_group_label>
    <description>To study clinical and genetic factors on tacrolimus dose normalized trough concentration.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood , paraffin-embedded liver biopsy, or saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        liver transplant patients' donors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:donors' recipients&#xD;
&#xD;
          -  Living liver transplant during 20070101 ~ 20151231 and only received liver&#xD;
             transplantation&#xD;
&#xD;
          -  Lab data at least 8 months,&#xD;
&#xD;
          -  Receiving tacrolimus as immunosuppressive drugs&#xD;
&#xD;
          -  Transplantation at 20 ~ 65 years old&#xD;
&#xD;
        Exclusion Criteria: donors' recipients&#xD;
&#xD;
          -  Retransplantation or multi-organ transplantation&#xD;
&#xD;
          -  Non-Asian&#xD;
&#xD;
          -  Positive for human immunodeficiency virus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rey-Heng Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Genetic polymorphisms</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

